Anne Li May 4th, 2017
Cancer Research UK, Cancer Research Technology (CRT), the charity’s commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer. The work will be carried out by scientists at Cancer Research UK’s Drug Discovery Unit at The University of Manchester, after the new family of compounds was identified using HitGen’s leading technology platform. This involved screening vast DNA encoded libraries, containing many hundreds of millions of small molecules with drug-like properties synthesized on chemically diverse scaffolds. A number of new small molecule leads for this important therapeutic target in lung cancer nominated by Cancer Research UK were revealed. This is the first license taken through the ongoing collaboration between CRT, Cancer Research UK’s Manchester Institute Drug Discovery Group and HitGen, who are eligible for milestone payments as the project progresses.
See original article at: http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-02-28-hitgen-and-cancer-research-uks-manchester-institute-enter-licence-agreement-in-lung-cancer